Clinical Pharmacology and Toxicology

This session focuses on the fundamental principles and clinical applications of pharmacokinetics (PK) and pharmacodynamics (PD), emphasizing how drugs are absorbed, distributed, metabolized, and eliminated in the human body, and how these processes influence therapeutic response and safety. The session will explore the biological and physiological factors that govern drug concentration–time profiles and their relationship to pharmacological effects, therapeutic benefits, and adverse outcomes. Special attention will be given to interindividual variability arising from genetic makeup, age, sex, organ function, disease states, and environmental influences. Speakers will discuss how PK/PD modeling and simulation are used to optimize dose selection, improve efficacy, and minimize side effects across different patient populations. The session will also address the role of biomarkers and biological data in predicting drug response and toxicity, enabling more precise and personalized treatment strategies. Clinical case studies will highlight how altered pharmacokinetics can lead to subtherapeutic effects or increased risk of toxicity, underscoring the importance of therapeutic drug monitoring and dose individualization. In addition, emerging approaches such as population pharmacokinetics, physiologically based pharmacokinetic (PBPK) modeling, and exposure–response analysis will be examined for their impact on drug development and regulatory decision-making. By integrating biological information with clinical outcomes, this session aims to enhance understanding of the balance between drug benefits and side effects, ultimately supporting safer, more effective, and evidence-based use of medicines in clinical practice.

This session highlights the growing role of personalized medicine and pharmacogenomics in optimizing drug therapy by tailoring treatments to an individual’s genetic and biological profile. It will explore how genetic variations influence drug metabolism, transport, target interaction, therapeutic response, and susceptibility to adverse drug reactions. The session emphasizes the integration of genomic, proteomic, and metabolomic data with clinical pharmacology to improve drug selection, dosing strategies, and treatment outcomes. Presentations will focus on clinically relevant gene–drug interactions, including polymorphisms affecting cytochrome P450 enzymes, drug transporters, and receptor targets, and how these variations can lead to treatment failure or increased toxicity if not appropriately considered. The biological basis of variability in drug response will be discussed alongside real-world examples demonstrating the benefits of pharmacogenomic-guided therapy in areas such as oncology, cardiology, psychiatry, and infectious diseases. Ethical, regulatory, and implementation challenges associated with pharmacogenomic testing in clinical practice will also be addressed, including data interpretation, accessibility, and clinical decision support. By linking biological information to clinical outcomes, this session underscores the potential of personalized medicine to reduce adverse effects, enhance therapeutic efficacy, and improve patient safety. The session aims to provide participants with a comprehensive understanding of how pharmacogenomics is transforming modern healthcare and shaping the future of precision pharmacotherapy.

This session focuses on the comprehensive process of drug discovery and development, from early target identification to clinical application, with an emphasis on integrating clinical pharmacology and toxicology to improve success rates and patient safety. It will explore the biological rationale behind drug target selection, mechanism of action studies, and lead optimization, highlighting how pharmacokinetic, pharmacodynamic, and toxicological data guide decision-making throughout the development pipeline. The session will address preclinical evaluation strategies, including in vitro and in vivo models used to assess efficacy, safety, and potential side effects before first-in-human studies. Discussions will also cover translational approaches that bridge laboratory findings with clinical outcomes, ensuring that biological information is effectively used to predict human response. Challenges such as drug attrition, unexpected toxicity, and variability in therapeutic response will be examined, along with innovative solutions such as model-informed drug development, biomarker-driven strategies, and adaptive trial designs. Regulatory expectations, ethical considerations, and risk–benefit assessment during development will also be highlighted. By emphasizing the integration of pharmacology and toxicology across all stages, this session aims to provide insights into developing safer, more effective medicines while reducing development timelines and costs, ultimately benefiting patients and healthcare systems worldwide.

This session addresses the principles and methodologies involved in the design and conduct of clinical trials, focusing on how sound scientific planning ensures reliable evaluation of drug safety, efficacy, and therapeutic benefit. It will explore different phases of clinical trials and their specific objectives, from early-phase safety and dose-finding studies to large-scale efficacy and post-marketing investigations. Emphasis will be placed on incorporating pharmacokinetic, pharmacodynamic, and toxicological data into trial design to optimize dosing strategies and minimize adverse effects. The session will discuss biological and clinical factors that influence trial outcomes, including patient selection, biomarkers, endpoints, and variability in drug response. Ethical considerations, regulatory requirements, and patient safety monitoring will be highlighted as critical components of high-quality clinical research. Real-world challenges such as protocol deviations, recruitment barriers, and data interpretation will be addressed, alongside innovative approaches including adaptive designs, decentralized trials, and the use of real-world evidence. By integrating biological insights with robust methodological frameworks, this session aims to enhance the reliability, efficiency, and ethical conduct of clinical trials, ultimately supporting evidence-based decision-making and improved patient care.

This session focuses on the critical practice of therapeutic drug monitoring (TDM), which involves measuring drug concentrations in biological fluids to optimize individual patient therapy, enhance therapeutic benefits, and minimize adverse effects. The session will highlight how pharmacokinetic and pharmacodynamic principles guide TDM, emphasizing the role of biological factors such as metabolism, organ function, age, genetics, and comorbidities in influencing drug levels and response. Clinical case studies will illustrate situations where TDM is essential, including drugs with narrow therapeutic windows, significant interindividual variability, or high toxicity potential, such as antiepileptics, immunosuppressants, anticoagulants, and certain antibiotics. Participants will learn how integrating laboratory measurements with patient-specific biological information allows for personalized dose adjustment, early detection of toxicity, and improved efficacy. The session will also explore the latest analytical technologies, including high-performance liquid chromatography, mass spectrometry, and point-of-care testing, which facilitate accurate and timely monitoring. Emerging trends such as model-informed precision dosing, pharmacogenetic-guided TDM, and integration with electronic health records will be discussed, demonstrating how advanced approaches enhance clinical decision-making. Ethical and regulatory considerations, along with practical challenges in implementing TDM programs in hospitals and clinics, will also be covered. By connecting biological insights with real-world therapeutic outcomes, this session aims to equip participants with the knowledge and tools necessary to optimize drug therapy, prevent adverse events, and support personalized medicine in routine clinical practice.

This session examines the mechanisms, clinical significance, and management of drug–drug and drug–food interactions, which can profoundly affect drug efficacy and safety. It will explore how biological factors, including genetic polymorphisms, enzyme activity, transporter expression, and organ function, influence the magnitude and clinical consequences of interactions. The session will provide detailed insights into pharmacokinetic interactions, such as changes in absorption, distribution, metabolism, and excretion, as well as pharmacodynamic interactions, where drugs or foods may enhance or antagonize therapeutic effects. Clinical case examples will illustrate scenarios where interactions lead to subtherapeutic response, toxicity, or unexpected adverse events, emphasizing the importance of monitoring and individualized management. The role of in vitro and in vivo studies, predictive modeling, and regulatory guidance in identifying and mitigating interactions will be discussed, along with strategies for patient counseling, dose adjustment, and clinical decision support. Emerging trends, including interaction profiling using genomics, metabolomics, and computational tools, will highlight innovative approaches to predicting and preventing adverse outcomes. By integrating biological knowledge with clinical practice, this session aims to equip participants with practical strategies to recognize, prevent, and manage interactions, ultimately optimizing patient safety and therapeutic effectiveness.

This session delves into the rapidly evolving field of translational and precision pharmacology, which bridges laboratory discoveries with clinical application to enhance drug efficacy and patient safety. The focus will be on how biological and molecular information—such as genomics, proteomics, metabolomics, and biomarker data—is integrated with pharmacokinetic and pharmacodynamic insights to tailor therapeutic strategies to individual patients. The session will explore translational approaches that link preclinical findings to human trials, highlighting the use of predictive models, in vitro–in vivo extrapolation, and physiologically based pharmacokinetic (PBPK) modeling to anticipate therapeutic outcomes and toxicity. Clinical examples will illustrate how precision pharmacology guides dose optimization, identifies patients at risk of adverse drug reactions, and enhances response prediction, particularly in areas such as oncology, immunotherapy, cardiovascular disease, and rare disorders. Speakers will discuss strategies for patient stratification, adaptive trial design, and biomarker-driven therapy, emphasizing the practical application of biological insights to improve clinical decision-making. Emerging tools, including artificial intelligence, machine learning, and systems pharmacology, will be highlighted for their role in integrating complex biological datasets to inform individualized therapy. Ethical, regulatory, and implementation challenges associated with precision pharmacology will also be addressed, including data interpretation, patient privacy, and accessibility. By combining foundational biological understanding with advanced analytical and clinical approaches, this session aims to demonstrate how translational and precision pharmacology transforms therapeutic practice, minimizes adverse effects, and maximizes the therapeutic benefit for diverse patient populations.

This session focuses on the development, clinical application, and safety evaluation of biologics, biosimilars, and advanced therapeutic modalities, including gene and cell therapies, monoclonal antibodies, and recombinant proteins. Emphasis will be placed on the biological mechanisms underlying these therapies, their pharmacokinetic and pharmacodynamic profiles, and the potential for immunogenicity, adverse reactions, and variability in patient response. The session will explore the regulatory and scientific considerations in the development of biosimilars, including demonstration of similarity to reference products in efficacy, safety, and immunogenicity. Case studies will illustrate the clinical benefits of biologics and advanced therapies in treating complex and chronic diseases, alongside strategies to monitor and manage side effects and optimize dosing. Participants will learn how preclinical and clinical data, along with translational insights, guide therapeutic decision-making and regulatory approval processes. Emerging areas such as cell-based therapies, CRISPR gene editing, RNA therapeutics, and nanomedicine will be discussed, highlighting both opportunities and challenges in clinical implementation. The session will also cover risk–benefit assessment, pharmacovigilance, and strategies for personalized application of these therapies. By integrating biological understanding, clinical pharmacology, and safety considerations, this session aims to equip participants with the knowledge to harness the potential of biologics and advanced therapies while ensuring patient safety and maximizing therapeutic efficacy.

This session focuses on the unique pharmacological and toxicological considerations in pediatric, geriatric, and other special populations, emphasizing how biological differences influence drug efficacy, safety, and dosing strategies. The session will explore age-related physiological changes, including variations in absorption, distribution, metabolism, and excretion, as well as the impact of comorbidities, polypharmacy, and organ dysfunction on drug response. In pediatrics, discussions will cover developmental pharmacokinetics, growth-dependent metabolism, and the challenges of establishing safe and effective dosing in neonates, infants, and adolescents. In geriatrics, the session will address altered pharmacodynamics, increased susceptibility to adverse drug reactions, and strategies to minimize polypharmacy risks while optimizing therapeutic outcomes. Special populations such as pregnant or lactating individuals, patients with renal or hepatic impairment, and those with rare genetic conditions will also be highlighted, with emphasis on biologically informed dose individualization and therapeutic monitoring. Clinical case studies and real-world examples will illustrate how tailored pharmacological strategies can reduce toxicity, enhance efficacy, and improve patient safety. Emerging tools such as physiologically based pharmacokinetic modeling, pharmacogenomic testing, and biomarker-guided therapy will be discussed for their role in predicting drug response and adverse events in these populations. Ethical, regulatory, and practical considerations in conducting clinical research and therapy optimization for vulnerable groups will also be addressed. By integrating biological, clinical, and regulatory perspectives, this session aims to provide participants with a comprehensive understanding of how to safely and effectively apply pharmacological principles in diverse patient populations, ultimately enhancing individualized care and therapeutic outcomes.

This session focuses on chemical, drug, and food toxicology, exploring how exposure to various substances impacts human health through biological, pharmacological, and molecular mechanisms. Emphasis will be placed on the absorption, distribution, metabolism, and excretion of chemicals, drugs, and food-derived toxins, as well as their effects on cellular and organ systems. Participants will learn how individual factors such as genetics, age, nutritional status, and comorbidities influence susceptibility to toxic effects and variability in clinical outcomes. The session will cover laboratory-based approaches, including in vitro and in vivo studies, biomarker detection, and analytical techniques for assessing toxicity, alongside risk assessment and exposure evaluation strategies. Case studies will highlight real-world examples such as drug overdoses, foodborne toxins, dietary supplements, environmental contaminants, and accidental or intentional chemical exposures, emphasizing strategies for prevention, early detection, and clinical management. Regulatory guidelines, safety standards, and global frameworks for chemical, drug, and food safety will be discussed to ensure compliance, protect public health, and guide therapeutic and industrial decision-making. Emerging trends, including computational toxicology, omics-based profiling, high-throughput screening, and predictive modeling, will be explored for their potential to improve accuracy, efficiency, and mechanistic understanding. By integrating biological knowledge with clinical, analytical, and regulatory perspectives, this session aims to equip participants with the expertise to identify, evaluate, and mitigate toxic effects, ultimately enhancing patient safety, public health, and safe therapeutic use.

This session focuses on the application of pharmacoepidemiology and real-world evidence (RWE) to understand drug utilization, effectiveness, safety, and outcomes in diverse populations, bridging the gap between clinical trials and routine clinical practice. The session will explore how biological, demographic, and clinical factors influence drug response and adverse events in large populations, providing insights beyond controlled experimental settings. Topics include study designs such as cohort, case–control, and cross-sectional studies, as well as observational databases, electronic health records, and registries used to generate RWE. The session will emphasize the role of pharmacovigilance, risk assessment, and post-marketing surveillance in identifying rare adverse events, long-term safety issues, and drug–drug interactions, highlighting how these insights inform clinical guidelines and regulatory decisions. Participants will learn how integrating pharmacokinetic, pharmacodynamic, genetic, and biomarker data with population-level analyses can improve understanding of variability in drug response, optimize treatment strategies, and enhance patient safety. Real-world examples will demonstrate how RWE informs policy, formulary decisions, comparative effectiveness research, and personalized therapy. The session will also address challenges in data quality, confounding factors, bias, and ethical considerations in observational research. Emerging approaches, including advanced analytics, machine learning, and predictive modeling, will be highlighted for their potential to improve study accuracy and clinical relevance. By linking biological knowledge with population-based evidence, this session aims to equip participants with the tools and understanding necessary to interpret and apply real-world data effectively, ultimately improving therapeutic decision-making, regulatory oversight, and patient outcomes.

This session explores the transformative role of digital health technologies and artificial intelligence (AI) in modern pharmacology and toxicology, highlighting how biological, clinical, and patient-specific data can be leveraged to improve drug development, therapy optimization, and patient safety. The session will cover applications such as AI-driven drug discovery, predictive modeling of pharmacokinetics and pharmacodynamics, virtual screening for toxicity, and biomarker identification. Clinical decision support systems, wearable devices, mobile health applications, and electronic health records will be discussed as tools to monitor therapeutic response, adherence, and adverse events in real-time. Emphasis will be placed on integrating biological information—genomics, proteomics, metabolomics—with computational models to personalize therapy, predict drug interactions, and minimize side effects. Case studies will illustrate how machine learning algorithms can optimize dosing, identify patients at risk of adverse drug reactions, and improve clinical trial design and patient recruitment. Regulatory and ethical considerations, including data privacy, algorithm transparency, and bias mitigation, will also be addressed to ensure safe and responsible implementation. Participants will gain insight into how AI and digital health are reshaping pharmacological research, drug safety monitoring, and clinical practice, enabling more precise, efficient, and patient-centered therapeutic strategies. By combining biological understanding with advanced analytics, this session aims to equip participants with knowledge and practical approaches to harness digital and AI-driven innovations for improved healthcare outcomes.

This session provides an in-depth exploration of clinical and medical toxicology, focusing on the diagnosis, management, and prevention of poisoning and adverse effects caused by drugs, chemicals, environmental agents, and natural toxins. The session will emphasize the biological and physiological mechanisms underlying toxicity, including absorption, distribution, metabolism, and elimination of toxic substances, as well as target organ effects and systemic responses. Participants will learn how patient-specific factors such as age, genetics, comorbidities, and organ function influence susceptibility to toxic effects, severity, and outcomes. Case-based discussions will highlight the clinical recognition of acute and chronic toxicity, dose-dependent versus idiosyncratic reactions, and the role of laboratory and biomarker testing in assessing exposure and predicting prognosis. The session will cover evidence-based management strategies, including decontamination, antidotes, supportive care, and monitoring of organ function, as well as emerging therapies and interventions that improve patient outcomes. Special emphasis will be given to high-risk populations, such as children, elderly, and patients with pre-existing medical conditions, where biological variability may alter drug toxicity profiles. Preventive strategies, including patient education, medication reconciliation, and public health interventions, will also be highlighted to reduce the incidence of accidental and intentional poisoning. By integrating biological understanding with clinical practice, this session aims to equip participants with the knowledge, diagnostic tools, and therapeutic strategies necessary to manage toxic exposures effectively, improve patient safety, and reduce morbidity and mortality associated with toxicological emergencies.

This session focuses on the principles, guidelines, and practices of regulatory and safety toxicology, which are critical for ensuring the safe development, approval, and use of pharmaceutical and chemical products. Emphasis will be placed on the integration of biological, pharmacological, and toxicological information to evaluate the risk–benefit profile of new and existing drugs, biologics, and chemical substances. Participants will gain insight into preclinical safety testing, including in vitro and in vivo toxicology studies, dose-response assessment, organ-specific toxicity, genotoxicity, carcinogenicity, reproductive toxicity, and immunotoxicity, as well as the translation of these findings to human risk assessment. The session will explore regulatory frameworks and guidelines from global agencies such as the FDA, EMA, ICH, and WHO, highlighting the requirements for data submission, safety evaluation, and pharmacovigilance. Case studies will illustrate how safety toxicology informs clinical trial design, dose selection, monitoring of adverse effects, and post-marketing surveillance. Emerging methodologies such as alternative testing models, high-throughput screening, computational toxicology, and predictive biomarkers will be discussed for their potential to enhance efficiency, reduce animal use, and improve predictive accuracy. By linking biological and mechanistic understanding with regulatory standards and clinical safety considerations, this session aims to equip participants with the knowledge and practical approaches necessary to conduct robust safety evaluations, ensure compliance with global regulations, and support the development of safe and effective therapeutics.

This session focuses on the assessment, management, and prevention of toxic exposures in environmental and occupational settings, highlighting how biological, chemical, and physical factors interact to affect human health. The session will examine the mechanisms by which environmental pollutants, industrial chemicals, heavy metals, pesticides, and airborne contaminants induce toxic effects, including cellular, molecular, and organ-level damage. Participants will learn how individual susceptibility is influenced by genetics, age, comorbidities, nutritional status, and cumulative exposure, and how these biological factors affect toxicity outcomes. Risk assessment strategies, including exposure measurement, dose-response relationships, and biomonitoring, will be discussed to identify populations at risk and guide regulatory interventions. The session will also cover occupational health toxicology, focusing on workplace hazards, industrial chemicals, and strategies for monitoring, prevention, and mitigation of occupational exposures. Epidemiological studies, case investigations, and real-world examples will illustrate the consequences of acute and chronic exposure on human health, including respiratory, neurological, reproductive, and systemic effects. Regulatory frameworks, international guidelines, and standards for safe exposure limits will be addressed, emphasizing the role of public health policies, workplace safety programs, and community awareness campaigns. Emerging trends such as the use of omics technologies, computational toxicology, and predictive modeling will be highlighted for their role in assessing environmental and occupational risks more effectively. By integrating biological understanding with clinical, regulatory, and preventive strategies, this session aims to equip participants with the tools to assess, manage, and prevent toxic exposures, ultimately protecting worker and community health.

This session explores forensic toxicology, emphasizing the detection, analysis, and interpretation of drugs, poisons, and other toxic agents in biological specimens for legal, clinical, and investigative purposes. The session will focus on the biological mechanisms of toxicity, including how drugs and chemicals are metabolized, distributed, and eliminated, and how these processes influence detection, interpretation, and determination of cause of death or impairment. Participants will learn about analytical techniques used in forensic investigations, including chromatography, mass spectrometry, immunoassays, and emerging high-throughput methods, and how these tools provide quantitative and qualitative data critical for legal and clinical decision-making. Case studies will illustrate practical challenges such as distinguishing therapeutic use from overdose, identifying delayed or cumulative toxicity, and interpreting postmortem redistribution effects. The session will also address the biological variability in drug metabolism, genetic factors, and interactions that can complicate forensic analysis. Legal, ethical, and regulatory considerations, including chain of custody, documentation, and admissibility of evidence, will be highlighted to ensure forensic accuracy and integrity. Additionally, emerging trends such as metabolomics, digital toxicology databases, and rapid point-of-care detection methods will be discussed for their potential to enhance forensic investigations. By combining biological, analytical, and legal perspectives, this session aims to equip participants with the knowledge and skills necessary to accurately detect and interpret toxic exposures, support justice, and contribute to public safety.

This session delves into genetic and molecular toxicology, focusing on how toxic agents interact with cellular and molecular pathways to induce DNA damage, gene mutations, chromosomal alterations, and epigenetic changes that can lead to disease, cancer, or heritable effects. Emphasis will be placed on understanding the biological mechanisms underlying genotoxicity, including oxidative stress, DNA adduct formation, and disruption of repair mechanisms, as well as the role of cellular signaling pathways in mediating toxicity. Participants will learn how genetic variability, polymorphisms, and epigenetic modifications influence individual susceptibility to toxic exposures and drug-induced adverse effects. The session will cover state-of-the-art methods for assessing molecular toxicity, including in vitro assays, high-throughput screening, omics technologies, and biomarker identification, highlighting their application in drug development, risk assessment, and regulatory decision-making. Real-world case studies will illustrate the translation of molecular toxicology findings to clinical and public health outcomes, including strategies to predict, prevent, and mitigate toxic effects. The role of computational modeling and bioinformatics in analyzing complex biological data will also be discussed, providing insight into mechanistic pathways and exposure-response relationships. Ethical, regulatory, and safety considerations in applying molecular toxicology findings will be emphasized, particularly in personalized medicine and precision pharmacology. By integrating molecular biology, pharmacology, and toxicology, this session aims to equip participants with a comprehensive understanding of how toxic agents affect genetic material, how these effects can be monitored and mitigated, and how molecular insights contribute to safer drug design, regulatory compliance, and improved patient outcomes.

This session focuses on reproductive and developmental toxicology, examining how chemical agents, drugs, and environmental exposures affect fertility, pregnancy, embryonic development, and long-term offspring health. The session will highlight the biological mechanisms underlying teratogenicity, gonadotoxicity, and reproductive system toxicity, including disruption of hormonal pathways, DNA damage, oxidative stress, and epigenetic modifications. Participants will learn how individual biological factors such as genetics, age, nutritional status, and pre-existing medical conditions influence susceptibility to reproductive and developmental toxicants. The session will cover preclinical models, in vitro assays, and in vivo studies used to assess reproductive and developmental toxicity, as well as clinical monitoring and biomarker strategies for risk evaluation in humans. Case studies will illustrate the consequences of exposure to drugs, industrial chemicals, and environmental toxins during critical periods of development, emphasizing strategies to prevent adverse outcomes, optimize maternal-fetal health, and ensure safe therapeutic use during pregnancy and lactation. Regulatory and ethical considerations, including risk assessment, labeling, and guidelines for drug use in reproductive populations, will be discussed to support evidence-based decision-making. Emerging trends, such as the application of genomics, epigenomics, and computational modeling, will be highlighted for their potential to enhance predictive accuracy and guide safer drug and chemical development. By integrating biological, clinical, and regulatory perspectives, this session aims to equip participants with the knowledge and tools necessary to understand, monitor, and mitigate reproductive and developmental risks, ultimately safeguarding maternal and child health while supporting therapeutic innovation.

This session explores neurotoxicology and immunotoxicology, focusing on how chemical agents, drugs, environmental toxins, and biologics impact the nervous and immune systems, influencing both acute and chronic health outcomes. The session will examine the biological mechanisms underlying neurotoxicity, including oxidative stress, excitotoxicity, mitochondrial dysfunction, and disruption of neurotransmission, as well as immune system toxicity through altered cytokine signaling, hypersensitivity reactions, and immune suppression. Participants will learn how genetic, developmental, and physiological factors influence susceptibility to neurotoxic and immunotoxic effects, highlighting vulnerable populations such as children, the elderly, and immunocompromised individuals. The session will cover preclinical models, in vitro assays, and biomarker-based approaches used to detect, monitor, and predict toxicity, as well as clinical evaluation strategies for assessing neurological and immunological adverse events. Case studies will illustrate real-world examples, including drug-induced neurotoxicity, vaccine-related immune reactions, environmental neurotoxins, and occupational exposures, emphasizing strategies to prevent, mitigate, and manage toxic outcomes. Regulatory, ethical, and safety considerations will be addressed, including guidelines for risk assessment, pharmacovigilance, and clinical monitoring. Emerging technologies, such as high-throughput screening, omics approaches, neuroimaging, and computational modeling, will be discussed for their role in advancing mechanistic understanding and improving predictive accuracy. By integrating biological, clinical, and regulatory perspectives, this session aims to equip participants with the knowledge, tools, and strategies to identify, prevent, and manage neurotoxic and immunotoxic effects, ensuring patient safety and advancing therapeutic innovation.